Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG002 in Advanced HER2-Positive Breast Cancer With Liver Metastases
NCT05263869Phase 2Unknown
- Sponsor
- Hangzhou Miracogen
- Start
- Mar 2022
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MRG002 in HER2-positive breast cancer, sponsored by Hangzhou Miracogen. Status: unknown.
02
Drugs
MRG002
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05263869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263869.